Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized, double-blind, placebo-controlled study of ARGX-113 in primary immune thrombocytopenia
2016-003038-26Phase 2Completed
- Sponsor
- argenx
- Start
- Nov 2016
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in immune thrombocytopenia (ITP) comparing ARGX-113 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Nov 2016; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2016-003038-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003038-26.